share_log

Cano Health Analyst Ratings

Benzinga ·  Nov 17, 2023 23:39
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/17/2023 -56.33% UBS $12 → $3.75 Downgrades Neutral → Sell
08/14/2023 -94.18% Credit Suisse $2.5 → $0.5 Maintains Neutral
08/11/2023 Jefferies Downgrades Buy → Hold
08/11/2023 -90.68% Citigroup $4 → $0.8 Downgrades Buy → Neutral
05/16/2023 -88.36% Piper Sandler $0.5 → $1 Maintains Underweight
05/12/2023 -70.89% Credit Suisse → $2.5 Reiterates Neutral → Neutral
01/06/2023 -85.44% UBS $12 → $1.25 Downgrades Buy → Neutral
01/05/2023 Wolfe Research Downgrades Outperform → Peer Perform
12/13/2022 -82.53% B of A Securities → $1.5 Reinstates → Underperform
11/16/2022 -41.78% Citigroup $7 → $5 Maintains Buy
11/10/2022 -65.07% Cowen & Co. $10 → $3 Downgrades Outperform → Market Perform
11/10/2022 Raymond James Downgrades Outperform → Market Perform
10/27/2022 -41.78% Credit Suisse $10 → $5 Downgrades Outperform → Neutral
09/07/2022 -18.49% Truist Securities → $7 Initiates Coverage On → Hold
08/10/2022 -53.42% Piper Sandler $4 → $4 Maintains Underweight
06/24/2022 -6.84% Raymond James → $8 Initiates Coverage On → Outperform
06/15/2022 -30.13% B of A Securities $8 → $6 Downgrades Buy → Neutral
05/11/2022 16.45% Credit Suisse $13 → $10 Maintains Outperform
05/11/2022 -53.42% Piper Sandler $5 → $4 Maintains Underweight
05/10/2022 -6.84% Citigroup $10 → $8 Maintains Buy
05/03/2022 -6.84% B of A Securities → $8 Initiates Coverage On → Buy
04/20/2022 74.67% UBS → $15 Initiates Coverage On → Buy
04/06/2022 -41.78% Piper Sandler $8.5 → $5 Downgrades Neutral → Underweight
03/16/2022 51.38% Credit Suisse $15 → $13 Maintains Outperform
11/10/2021 51.38% Piper Sandler $11 → $13 Maintains Neutral
10/20/2021 97.96% Jefferies → $17 Initiates Coverage On → Buy
10/19/2021 28.09% Piper Sandler → $11 Initiates Coverage On → Neutral
10/01/2021 121.25% Wolfe Research → $19 Initiates Coverage On → Outperform
09/21/2021 132.89% Citigroup → $20 Initiates Coverage On → Buy
09/10/2021 109.6% Cowen & Co. → $18 Initiates Coverage On → Outperform
08/02/2021 109.6% Credit Suisse → $18 Initiates Coverage On → Outperform

What is the target price for Cano Health (CANO)?

The latest price target for Cano Health (NYSE: CANO) was reported by UBS on November 17, 2023. The analyst firm set a price target for $3.75 expecting CANO to fall to within 12 months (a possible -56.33% downside). 9 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Cano Health (CANO)?

The latest analyst rating for Cano Health (NYSE: CANO) was provided by UBS, and Cano Health downgraded their sell rating.

When is the next analyst rating going to be posted or updated for Cano Health (CANO)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cano Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cano Health was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.

Is the Analyst Rating Cano Health (CANO) correct?

While ratings are subjective and will change, the latest Cano Health (CANO) rating was a downgraded with a price target of $12.00 to $3.75. The current price Cano Health (CANO) is trading at is $8.59, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment